Market Currents
Galena Biopharma GALE +5.4%) moves up after releasing positive data from its phase 1/2 clinical...
-
Friday, October 26, 2012, 3:03 PM ETGalena Biopharma GALE +5.4%) moves up after releasing positive data from its phase 1/2 clinical trial of tumor drug NeuVax. According to the trial, the drug showed a consistent reduction of circulating tumor cells in vaccinated patients. Final results will be reported at the San Antonio Breast Cancer Symposia in December 2012.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
